The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
CAR-T Meeting 2020 | Cost-effectiveness of CAR T-cell therapy
Carin Al Uyl-de Groot
• 12 Feb 2020
Carin Al Uyl-de Groot, PhD, Erasmus University Rotterdam, Rotterdam, The Netherlands, discusses the evaluation of the cost-effectiveness of CAR T-cell therapy for pediatric acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL). This interview took place at the 2nd European CAR T-Cell Meeting in Sitges, Spain.
